HER2-LOW BREAST CANCER

This study is looking at how well a drug called trastuzumab-rezetecan works and how safe it is for people with HER2-positive or HER2-low breast cancer. About 300 adults who are already scheduled to receive this drug as part of their care will be followed. Researchers will track s…

This study tests a new drug called BL-M07D1 against standard chemotherapy in 566 adults with HER2-low breast cancer that cannot be removed by surgery or has spread. The goal is to see if BL-M07D1 can slow cancer growth or improve survival. Participants are randomly assigned to re…

This study is observing 800 Chinese adults with advanced HER2-positive or HER2-low breast cancer who are taking trastuzumab deruxtecan (T-DXd). Researchers will track how long the drug controls the cancer and note any side effects in real-world settings. The goal is to understand…

This study tests a combination of two drugs (disitamab vedotin and bevacizumab) in people with HER2-low breast cancer that has spread and stopped responding to a prior treatment called T-DXd. About 37 adults will receive the combo to see if it shrinks tumors and how safe it is. T…

This study tests two antibody drug conjugates (datopotamab deruxtecan and trastuzumab deruxtecan) given one after the other in people with HER2-negative metastatic breast cancer that has worsened after prior treatment. The goal is to see if this sequence can shrink tumors or slow…

This study is for people with advanced breast cancer that has spread. It tests a special PET scan that looks for a protein called HER2 on cancer cells. The goal is to see if this scan can better predict who will benefit from a targeted drug called T-DXd, helping doctors choose th…

This study examines genetic changes in HER2-low breast cancer, a type that is not easily treated with standard HER2 therapies. Researchers will analyze tumor and blood samples from 255 women to see how these gene patterns relate to survival. The goal is to better understand the d…